176 related articles for article (PubMed ID: 37231349)
21. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
22. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
23. Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients.
Milazzo L; van den Bogaart L; Sollima S; Oreni L; Lai A; Morena V; Bonazzetti C; Ridolfo Anna L; Antinori S
Eur J Intern Med; 2020 May; 75():50-54. PubMed ID: 31980330
[TBL] [Abstract][Full Text] [Related]
24. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
25. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
26. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
27. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
[TBL] [Abstract][Full Text] [Related]
28. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
29. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus.
Guardigni V; Toschi A; Badia L; Rosselli Del Turco E; Salsi E; Cristini F; Sighinolfi L; Fabbri G; Massari M; Cuomo G; Viale P; Verucchi G;
AIDS; 2021 Oct; 35(12):1967-1972. PubMed ID: 34101631
[TBL] [Abstract][Full Text] [Related]
30. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
31. Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis.
Gragnani L; Lorini S; Martini L; Stasi C; Visentini M; Petraccia L; Marello N; Monti M; Marri S; Madia F; Ricca V; Zignego AL
Clin Rheumatol; 2022 Jan; 41(1):147-157. PubMed ID: 34409558
[TBL] [Abstract][Full Text] [Related]
32. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study.
Di Stasio D; Lucchese A; Romano A; Adinolfi LE; Serpico R; Marrone A
Clin Oral Investig; 2022 Aug; 26(8):5409-5417. PubMed ID: 35477818
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study.
Ibáñez-Samaniego L; Rapado-Castro M; Cabrero L; Navarrete C; García-Mulas S; Ahumada A; Marquez L; Pérez MD; Rincon D; Bañares R; Garcia-Martinez R
Eur J Neurol; 2022 Feb; 29(2):400-412. PubMed ID: 34634159
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment.
Romano C; Tortorella O; Dalla Mora L; Di Stasio D; Sellitto A; Adinolfi LE; Marrone A
Front Immunol; 2022; 13():882064. PubMed ID: 35479086
[TBL] [Abstract][Full Text] [Related]
35. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
36. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
37. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
Abdelhamed W; El-Kassas M
J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
